1. Background {#sec1-1}
=============

Rheumatoid arthritis is a common autoimmune disease that is related to advanced disability, systemic inflammation, and early death ([@ref1]). Although the cause of rheumatoid arthritis is poorly known, pro-inflammatory cytokines such as tumor necrosis factor α (TNFα), as a mediator protein in the immune system, play an important role in the pathogenesis of rheumatoid arthritis ([@ref2], [@ref3]).TNF as a signaling molecule controls intercellular communication that mediates inflammation, apoptosis, immunoregulation, and cellular proliferation/differentiation ([@ref4]). The main role of TNF-α is in the induction of inflammation and immunity through activating immune cells in reaction to infections and tissue injury. The moderated expression of TNF is therefore fundamental to attack infections and raise tissue repair. However, the dysregulation of TNF production and signaling can lead to chronic inflammation, which may uncontrolled inflammation and autoimmune disease ([@ref5]). Signal transduction is mediated- through two distinct receptors TNFR1 (TNFRSF1, CD120a) and TNFR2 (TNFRSF2, CD120b). TNFR1 is ubiquitously expressed in nearly all tissue cells, probably due to the extensive activity range of TNF's. TNFR2 is expressed in a limited manner on certain cells of the immune system, including T-regulatory cells (Tregs), endothelial cells, and neuronal tissues and its expression can be greatly controlled by the cellular function and cell type. Both receptors are type I transmembrane glycoproteins with extracellular and intracellular components. Binding of TNF to TNFRs leads to signals transducion through both receptors. The current progress in the understanding of the pathogenetic mechanisms of rheumatoid arthritis and use of genetic engineering techniques have resulted in designing new-biologic drugs such as TNFRs that are able to inhibit the function of several cytokines([@ref6], [@ref7]) In this study, we survey the cloning and the expression of a TNF receptor2 in Chinese hamster ovary (CHO) cells, as well as purifying recombinant protein used in the treatment of collagen-induced arthritis (CIA) in Balb/c mice.

2. Objectives {#sec1-2}
=============

The aim of this study was to evaluate the therapeutic effectuality of the recombinant human TNFR2 on collagen-induced arthritis (CIA) in mice. We have proposed that arthritis symptoms would be decreased with the receptor-ligand complex constitution between rTNFR2 and TNF-α, consequently the TNF-α cytokine will be reduced in synovial fluid.

3. Materials and Methods {#sec1-3}
========================

3.1. Animals {#sec2-1}
------------

Female Balb/c mice (Inbred strain of mouse) of 16--20 week age were obtained from Razi Institute (Karaj, Iran). Mice were keeped under standard conditions. All experiments were performed according to the Animal Care and Use Protocol of Shahid Beheshti University of Medical Sciences (Tehran, Iran) and approved by the Ethical Committee of the University.

3.2. Expression, and Purification of a TNF Receptor 2 {#sec1-4}
-----------------------------------------------------

The plasmid encoding of TNF receptor protein obtained from our previous study ([@ref8]). It was transferred to the CHO K1 cells. Glycosylated TNFR2 protein was expressed in CHO (Chinese hamster ovary) cells and purified by Ni-NTA His-Tag (nickel-charged nitrilotriacetic acid Histidine Tag) Affinity Chromatography and gel filtration.

3.3. Collagen-Induced Arthritis and Medicine Treatment {#sec2-2}
------------------------------------------------------

Bovine type II collagen (Chondrex, USA) was prepared according to Luo Y *et al*. at a concentration of 1mg.mL^-1^ with an equal volume of Freund's complete adjuvant (FCA) (Sigma, USA). At the beginning of the experiments (on day1), the female Balb/c mice, were injected intradermally at the base of the tail with 1mL of CII emulsion. On day 21, mice were boosted with an intraperitoneal injection of 100 µg type II collagen. After the second injection of CII, all immunized mice were divided randomly into 4 groups (n = 5 per group). The normal group was without any immunization. The control group (CIA group) was treated with PBS. The positive control group was treated with methotrexate (MTX, Sigma Aldrich, USA) (1.5 mg.kg^-1^). The treated mice were injected with TNFR2 protein intraperitoneally (1 mg.kg^-1^). TNFR2 protein and methotrexate were administered daily during the second week from day 21 to 36 after immunization ([@ref9]).

3.4. Evaluation of Progression of Paw and Joint Edema {#sec2-3}
-----------------------------------------------------

From day 21 of the primary immunization, the paw widths and the circumference was measured every three days with a Vernier caliper by an independent observer without prior awareness of the experimental groups. Each paw and joint was measured three times ([@ref10]).

3.5. Assessment of Arthritis {#sec2-4}
----------------------------

On day 37, mice were sacrificed and their right hind limbs were fixed in 4% neutral buffered formalin for 24 h and decalcified in 10% ethylenediaminetetraacetic acid (EDTA). Next, they were embedded in paraffin. The sections of 6 µm were prepared with hematoxylin and eosin (H&E) method and observed by light microscopy ([@ref11]).

3.6. Evaluation of TNF-α, IL-1β, IL-6 and IL-10 Levels in Mice Serum {#sec2-5}
--------------------------------------------------------------------

Levels of total TNF-α, IL-1β, IL-6, and IL-10 in the serum samples of mice were analyzed by enzyme-linked immunosorbent assay (ELISA) Duoset kits (R&D Systems Inc., USA). The concentrations of these cytokines were calculated from the standard curves.

3.7. Statistical Analysis {#sec2-6}
-------------------------

Results are reported as mean±S.E.M. Statistical analysis was evaluated by Student's t-test (between the control and disease), two-way (treatment×time) ANOVA (Analysis of Variance), and one-way ANOVA followed by Dunnett's t-test. The P-values were considered \*\< 0.05, \*\*P \< 0.01 and \*\*\*P \< 0.001 for significant results.

4. Results {#sec1-5}
==========

4.1. Expression and Purification of Recombinant TNFR Protein {#sec2-7}
------------------------------------------------------------

**[Figure 1](#fig001){ref-type="fig"}** demonstrates the results of the western blot analysis of the purified protein. It shows the glycosylated form of TNF receptor according to Corti A. *et al* report ([@ref12]).

4.2. Wide-Ranging of Paws and Knee Joints: {#sec2-8}
------------------------------------------

The width changes of hind paws and knee joints for days 21 to 36 are presented in **[Tables 1](#table001){ref-type="table"}, [2](#table002){ref-type="table"}**. The mice in treated groups with TNFR2 protein were remarkably different from those in the control group since they show a swelling reduction of paws and knee joints on day 30.

4.3. Histological Changes {#sec2-9}
-------------------------

Histological analysis displays the inhibitory traces of TNFR2 on the knee joints in the CIA mice. The non-immunized group indicates no histopathological changes but shows normal articular cartilage (**[Fig. 2A](#fig002){ref-type="fig"}**). In the knee joints of the control group (CIA group) histopathological changes such as cartilage hyperplasia, synovial hyperplasia, and the formation of pannus were observed (**[Fig. 2B](#fig002){ref-type="fig"}**).

The group treated with recombinant protein (1 mg.kg^-1^) show reduced pathological changes in knee joints (**[Fig. 2C](#fig002){ref-type="fig"}**). In the group treated with MTX showed a little bit increase in synovial hyperplasia and cartilage hyperplasia in knee joints (**[Fig. 2D](#fig002){ref-type="fig"}**).

4.4. Measurement of TNFα˛, IL-1β, IL-6, IL-10 in Mice Sera {#sec2-10}
----------------------------------------------------------

To study the levels of the inflammatory cytokines on day 36 after the first injection, the levels of TNF-α, IL-1β, IL-6, and IL-10 were surveyed by ELISA in blood samples. The levels of the cytokines of the normal group (Non-immunized group), the control group (CIA group), and the groups treated with MTX and TNFR2 were evaluated.

As displayed in **[Figure 3](#fig003){ref-type="fig"}**, the levels of TNF-α, IL-1β, and IL-6, in the serum of the CIA group were remarkably higher than those in the normal group (P \< 0.01).

It was shown that the levels of TNF-α, IL-1β, and IL-6 in groups treated with recombinant protein and MTX were clearly lower than those of CIA group (P \< 0.01, P \< 0.001).

As shown in **[Figure 3](#fig003){ref-type="fig"}**, the level of TNF-10 in the serum of the CIA group was lower than that in the normal group (P \< 0.01). In comparison, the level TNF-10 in the serum of the groups treated with the recombinant protein and MTX was clearly higher than the CIA group (P \< 0.01).

5. Discussion {#sec1-6}
=============

RA is an advanced chronic disease in human due to antigen precipitation in the joints. This disease is composed of the pannus formation, synovial cellular hyperplasia, infiltrations of the inflammatory cells, autoantibody production (rheumatoid factor and anti-citrullinated protein antibody (ACPA), cartilage and bone destruction, and many different cytokines ([@ref13], [@ref14]).TNF-α a cytokines in the synovial fluid of RA, is mostly produced by activated immune cells in reaction to infections and tissue damage. TNF-α is upstream to the proinflammatory cytokines network ([@ref6], [@ref15]). One of the main properties of TNFα is inducing secretion of pro-inflammatory cytokines such as IL-1 and IL-6.

It has been also proven that cytokines like TNF-α, IL-1β, and IL-6 are produced in high quantities in all of the rheumatoid synovial membrane samples ([@ref16]). The purpose of the present study was to investigate the therapeutic value of recombinant TNFR2 on CIA in balb/c mice. Our results showed that paw and knee edema in CIA decreased with the administration of the recombinant TNFR2 protein to CIA mice during a two-week period. On the other hand, histological analysis revealed that this protein decreases the histopathological signs such as synovial hyperplasia, pannus formation, and cartilage hyperplasia, and bone erosion. The results also showed that recombinant protein affects the cytokines production by immune cells. This effect might be due to the fact that TNFα and IL-1 are critical cytokines in the procedure of chronic joint inflammation and the eventual destruction at the junction of the synovial lining in the joint capsule with the cartilage and bone. IL-1, IL6, and TNFα pleiotropic produced predominantly by macrophages. IL-1 and TNFα definitely induced destructive matrix metalloproteinases, such as MMP-1 (collagenase) and MMP-3 (stromelysin) that, in turn, cause cartilage damage and induce bone resorption in *in vitro* cultures. Moreover, IL-6 may prevent bone synthesize and affect bone resorption through its stimulatory in osteoclasts ([@ref17]). IL-6 is recognized as a pro-inflammatory cytokine that is activated after binding to a receptor. This protein affects the maturation and activation of B and T cells, macrophages, osteoclasts, and chondrocytes and also plays a crucial role in bone and cartilage degradation. IL-10 is an anti-inflammatory and immunosuppressive cytokine that has been shown to regulate endogenous proinflammatory cytokine synthesis in RA synovial tissue. In this work, neutralization of endogenously produced IL-10 in the RA synovial membrane cultures resulted in a remarkable increase in the levels of proinflammatory cytokines TNF-α and IL-1β. IL-10 has also been shown to suppress the synthesis of IL-1β, IL-6, and TNF-α ([@ref18], [@ref19]).

TNFα as a therapeutic target plays a key role in rheumatoid arthritis treatment. This theory has been successfully examined in animal models with, collagen-induced arthritis and the assays have paved the way for clinical trials of anti-TNF therapy in patients with rheumatoid arthritis. Since TNFR2 plays a crucial role in tissue regeneration and immune regulation. The ligands that successfully activate TNFR2 have been used as new therapeutics for treatment inflammatory autoimmune diseases such as RA ([@ref7]).

Studies have demonstrated that two different types of soluble TNF receptor (sTNFR) and trivalent soluble TNF Receptor2 or some anti-tumor necrosis factor antibodies (fusing a sTNFR with the Fc region of IgG1) prevent collagen arthritis in mice. We used insoluble recombinant TNFR2 (total TNFR2) for the treatment of mice CIA.

As TNFα is homotrimer and it appears that TNFR2 monomers to spontaneously form a hemotrique ligand (biologically active protein) that may have suitable docking sites and theoretically has a higher affinity to TNFα. This can offer a molecular basis for the block anti-TNF drug in treating RA. Additionally, it has been recently shown that the expression of TNFR2 on hematopoietic cells decreases the intensity of TNF-driven arthritis. Finally, regulatory T cell (Treg) has appeared as likely mediator of the anti-inflammatory factors of TNFR2 ([@ref20], [@ref21]).

According to Köhne's study the glycosylation of secreted recombinant TNFR-IgG1 fusion protein impacted its intracellular transport and secretion of other variants with binding properties similar to the fully glycosylated protein ([@ref22]).

We used recombinant TNFR2 intra peritoneal administrated for fourteen days without interruption from the day 21 to 36, Based on our results, our approach, could effectively improve clinical symptoms of mice i.e., showed by the dramatic decrease in inflammatory swelling in the knee joints and the paws, and the reduced pathological changes in knee joints and this recombinant protein remarkably decreased the infiltration of inflammatory cells into the synovial area and prevented bone and cartilage from erosion. The serum levels of cytokines TNF-α, IL-1β, and IL-6 significantly reduced in groups treated with the recombinant TNFR2. Our findings suggest that complete TNFR2 in rheumatic arthritis in mice and suggests a suitable strategy is for anti-inflammatory therapy in RA. However, we recommend further studies using administrate different doses of this recombinant protein to CIA.

6. Conclusions {#sec1-7}
==============

The spite of the different types of drugs usage for reducing the inflammation in patients with Rheumatoid and being many reports about their side effects, our findings show that administration of recombinant TNF receptor has blocked or protected joints from progressive damages. This study suggests that the anti-arthritic effectiveness of TNFR2 will repress the symptoms of rheumatoid arthritis. Besides, it seems that TNFR2 is a strong candidate for the treatment of the RA disease.

This article was extracted from Shahla Korani's Ph.D. thesis conducted in the Cellular & Molecular Biology Research Center of Shahid Beheshti University of Medical Sciences. The study was funded by the deputy of Shahid Beheshti University of Medical Sciences (grant number 5061) adhering to the ethics code IR.SBMU.RAM. REC.1394.82.7.

![Western blot analysis result of the purified recombinant TNFR2 protein (75 kDa).](ijb-2019-01-e2153-g001){#fig001}

![Histology of CIA mice: (A) The normal cartilage and synovial without inflammation (B) The joints of control mice with obvious synovial hyperplasia, cartilage hyperplasia and pannus formation (C) The joints of recombinant TNFR2 treated mice with moderated synovial hyperplasia (D) The joints of MTX treated mice with moderated synovial hyperplasia and cartilage hyperplasia c: cartilage hyperplasia; p, pannus formation and s, synovial hyperplasia](ijb-2019-01-e2153-g002){#fig002}

![Level of serum TNFα, IL1b. IL6 and IL10 in CLA mice (mean ± S.E.M, n = 5). Effect of recombinant TNFR2 on the regulation of the serum inflammatory cytokines in CLA mica\
\*\* P \< 0.01 compared with the control group\
\*\*\* P \< 0.001 compared with the control group\
\#\# P \< 0.01 compared with the normal group](ijb-2019-01-e2153-g003){#fig003}

###### 

Effect of recombinant TNFR2 on PAW joints wellings of CIA mice. Two-way ANOVA revealed significant effects between control and treated groups

              Control                                                Disease                                                  MTX                                                    TNFR2
  ----------- ------------------------------------------------------ -------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------
              **Mean ± SEM**                                         **Mean ± SEM**                                           **Mean ± SEM**                                         **Mean ± SEM**
  **Day21**   0.201 ± 0.003[\*\*\*](#t1fn002){ref-type="table-fn"}   0.215 ± 0.003^[\#\#\#](#t1fn003){ref-type="table-fn"}^   0.213 ± 0.002[\*\*](#t1fn001){ref-type="table-fn"}     0.191 ± 0.002[\*\*\*](#t1fn002){ref-type="table-fn"}
  **Day24**   0.206 ± 0.002[\*\*\*](#t1fn002){ref-type="table-fn"}   0.220 ± 0.002^[\#\#\#](#t1fn003){ref-type="table-fn"}^   0.221 ± 0.003[\*\*\*](#t1fn002){ref-type="table-fn"}   0.194 ± 0.003[\*\*\*](#t1fn002){ref-type="table-fn"}
  **Day27**   0.210 ± 0.004[\*\*\*](#t1fn002){ref-type="table-fn"}   0.224 ± 0.004^[\#\#\#](#t1fn003){ref-type="table-fn"}^   0.214 ± 0.004[\*\*](#t1fn001){ref-type="table-fn"}     0.196 ± 0.004[\*\*](#t1fn001){ref-type="table-fn"}
  **Day30**   0.208 ± 0.007[\*\*\*](#t1fn002){ref-type="table-fn"}   0.225 ±0.007^[\#\#\#](#t1fn003){ref-type="table-fn"}^    0.213 ± 0.001[\*\*](#t1fn001){ref-type="table-fn"}     0.190 ± 0.002[\*\*\*](#t1fn002){ref-type="table-fn"}
  **Day33**   0.206 ± 0.005[\*\*\*](#t1fn002){ref-type="table-fn"}   0.226 ± 0.005^[\#\#\#](#t1fn003){ref-type="table-fn"}^   0.212 ± 0.002[\*\*\*](#t1fn002){ref-type="table-fn"}   0.191 ± 0.001[\*\*\*](#t1fn002){ref-type="table-fn"}
  **Day36**   0.206 ± 0.004[\*\*\*](#t1fn002){ref-type="table-fn"}   0.225 ± 0.004^[\#\#\#](#t1fn003){ref-type="table-fn"}^   0.209 ± 0.002[\*\*\*](#t1fn002){ref-type="table-fn"}   0.193 ± 0.002[\*\*\*](#t1fn002){ref-type="table-fn"}

\*\*P \< 0.01 compared with the Disease Group

\*\*\*P \< 0.001 compared with the Disease Group.

\#\#\# P \< 0.001 compared with the Normal Group

###### 

Effect of recombinant TNFR2 on knee joints wellings of CIA mice. Two-way ANOVA revealed significant effects between control and treatment groups

              Control                                                Disease                                                    MTX                                                    TNFR2
  ----------- ------------------------------------------------------ ---------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------
              **Mean ± SEM**                                         **Mean ± SEM**                                             **Mean ± SEM**                                         **Mean ± SEM**
  **Day21**   0.2744 ± 0.003[\*\*](#t1fn005){ref-type="table-fn"}    0.289 ± 0.003^[\#\#](#t1fn007){ref-type="table-fn"}^       0.287 ± 0.002[\*\*](#t1fn005){ref-type="table-fn"}     0.286 ± 0.001[\*](#t1fn004){ref-type="table-fn"}
  **Day24**   0.276 ± 0.003[\*\*\*](#t1fn006){ref-type="table-fn"}   0.291± 0. 0.003^[\#\#\#](#t1fn008){ref-type="table-fn"}^   0.290 ± 0.002[\*\*](#t1fn005){ref-type="table-fn"}     0.289 ± 0.002[\*\*](#t1fn005){ref-type="table-fn"}
  **Day27**   0.27 ± 0.004[\*\*\*](#t1fn006){ref-type="table-fn"}    0.296 ± 0.004^[\#\#\#](#t1fn008){ref-type="table-fn"}^     0.296± 0.004[\*\*\*](#t1fn006){ref-type="table-fn"}    0.294 ± 0.003[\*\*\*](#t1fn006){ref-type="table-fn"}
  **Day30**   0.278 ± 0.006[\*\*\*](#t1fn006){ref-type="table-fn"}   0.298 ± 0.006^[\#\#\#](#t1fn008){ref-type="table-fn"}^     0.287 ± 0.002[\*](#t1fn004){ref-type="table-fn"}       0.285 ± 0.002[\*\*](#t1fn005){ref-type="table-fn"}
  **Day33**   0.279 ± 0.006[\*\*\*](#t1fn006){ref-type="table-fn"}   0.298 ± 0.006^[\#\#\#](#t1fn008){ref-type="table-fn"}^     0.286 ± 0.004[\*\*](#t1fn005){ref-type="table-fn"}     0.285 ± 0.003[\*\*](#t1fn005){ref-type="table-fn"}
  **Day36**   0.278 ± 0.007[\*\*\*](#t1fn006){ref-type="table-fn"}   0.299 ± 0.007^[\#\#\#](#t1fn008){ref-type="table-fn"}^     0.284 ± 0.005[\*\*\*](#t1fn006){ref-type="table-fn"}   0.28 ±0.004[\*\*\*](#t1fn006){ref-type="table-fn"}

\* P \< 0.05 compared with the disease group

\*\* P \< 0.01 compared with the disease group

\*\*\* P \< 0.001 compared with the disease group

\#\# P \< 0.01 compared with the normal group

\#\#\# P \< 0.001 compared with the normal group
